Evidence map›Paper›PMID 40762906›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

Role of viral coinfection in post-pandemic invasive Group A streptococcal infections in adults, a nation-wide cohort study (iGASWISS).

S Musumeci, A MacPhail, M Weisser Rohacek, A Erba, D Goldenberger, C Lang, E Colin-Benoit, S L Leib, P Sendi, C Chuard and 29 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Tracing the recent evolution of Group AEmerging microbes & infections · 2026
    Review
  2. Article
  3. Lysosomal permeabilization by Group AInfection and immunity · 2026
    Article
  4. Article
  5. Lysosomal permeabilization by Group AbioRxiv : the preprint server for biology · 2025
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

S MusumeciDepartment of Infectious Diseases, Department of Diagnostics, University Hospital Geneva, Geneva, Switzerland. smuu@hug.ch.
A MacPhailDepartment of Infectious Diseases, Monash Health, Melbourne, Australia.
M Weisser RohacekDivision of Infectious Diseases, University Hospital Basel, Basel, Switzerland.
A ErbaDivision of Infectious Diseases, University Hospital Basel, Basel, Switzerland.
D GoldenbergerClinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland.
C LangClinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland.
E Colin-BenoitDepartment of Infectious Diseases, University Hospital Bern, University of Bern, Bern, Switzerland.
S L LeibInstitute for Infectious Diseases, University of Bern, Bern, Switzerland.
P SendiInstitute for Infectious Diseases, University of Bern, Bern, Switzerland.
C ChuardUnit of Infectious Diseases and Laboratory of Clinical Microbiology, Cantonal Hospital of Fribourg, Fribourg, Switzerland.
V ErardUnit of Infectious Diseases and Laboratory of Clinical Microbiology, Cantonal Hospital of Fribourg, Fribourg, Switzerland.
C FournierUnit of Infectious Diseases and Laboratory of Clinical Microbiology, Cantonal Hospital of Fribourg, Fribourg, Switzerland.
L CobuccioDepartment of Medicine, Division of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland.
F TaginiDepartment of Medicine, Division of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland.
C BertelliInstitute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland.
L SennDepartment of Medicine, Division of Infectious Diseases, University Hospital Lausanne, Lausanne, Switzerland.
R SommersteinDepartment of Infectious Diseases, University Hospital Bern, University of Bern, Bern, Switzerland.
G BlättlerFaculty of Healthcare Sciences and Medicine, University of Lucerne and Klinik St. Anna, Lucerne, Switzerland.
C Vieira GomesDepartment of Infectious Diseases, Central Institute, Hospital of Valais, Valais, Switzerland.
M MorazDepartment of Infectious Diseases, Central Institute, Hospital of Valais, Valais, Switzerland.
S EmonetDepartment of Infectious Diseases, Central Institute, Hospital of Valais, Valais, Switzerland.
C StrahmDivision of Infectious Diseases, Infection Prevention and Travel Medicine, Health Ostschweiz, Cantonal Hospital of St Gallen, St Gallen, Switzerland.
P KohlerDivision of Infectious Diseases, Infection Prevention and Travel Medicine, Health Ostschweiz, Cantonal Hospital of St Gallen, St Gallen, Switzerland.
S N SeiffertDivision of Human Microbiology, Center for Laboratory Medicine, St. Gallen, Switzerland.
K HerzogDepartment of Infectious Diseases, Institute of Laboratory Medicine, Spital Thurgau AG, Thurgau, Switzerland.
D Vuichard GysinDepartment of Infectious Diseases, Institute of Laboratory Medicine, Spital Thurgau AG, Thurgau, Switzerland.
S D BruggerDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
O NolteInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
A EgliInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
D WellerDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
A M AndrianakiDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
A S ZinkernagelDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
D-L VuOCS (Office Cantonal de la Santé) of the Geneva Canton, Geneva, Switzerland.
A Uribe CaparrosOCS (Office Cantonal de la Santé) of the Geneva Canton, Geneva, Switzerland.
G LaurieOCS (Office Cantonal de la Santé) of the Geneva Canton, Geneva, Switzerland.
N GaiaDepartment of Infectious Diseases, Department of Diagnostics, University Hospital Geneva, Geneva, Switzerland.
V LazarevicDepartment of Infectious Diseases, Department of Diagnostics, University Hospital Geneva, Geneva, Switzerland.
P FrançoisDepartment of Infectious Diseases, Department of Diagnostics, University Hospital Geneva, Geneva, Switzerland.
J SchrenzelDepartment of Infectious Diseases, Department of Diagnostics, University Hospital Geneva, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDuring the winter season of 2022-2023, numerous countries experienced a surge in invasive Streptococcus pyogenes (iGAS) infections. The role of viral coinfections in the post-COVID surge has not been elucidated. We report nation-wide data describing clinical presentation, microbiological characteristics, and associations with viral infection in adults during this period.

methodsA multicenter retrospective cohort study was conducted across 10 hospitals in Switzerland, including adults (> 16 years old) with iGAS infection from November 2022 to February 2023. Descriptive analysis was performed. A multivariable logistic regression model was fitted to assess the impact of viral coinfection. In addition, genetic analysis was performed in available isolates.

resultsA total of 194 patients were included, with a median age of 50 years (interquartile range [IQR]: 37-69). 17/194 (8.8%) were immunosuppressed and 40/194 (20.6%) exhibited concomitant viral infections, predominantly Influenza A (21/40, 53%). Illness severity was high: 65/194 (33.5%) of cases necessitated admission to an intensive care unit (ICU), and the 30-day mortality was 4% (n = 8). Among the available strains for genetic analysis (n = 48), heterogeneity was found although ST28-emm1 isolates (also known as M1UK) was predominant (22/48).

conclusionThe post-COVID iGAS surge in Switzerland was associated with high levels of morbidity and mortality in immunocompetent adults. M1UK was predominant within the iGAS strains circulating in Switzerland during the study period and viral coinfection was a predictor for ICU admission and mortality.

Indexed as

CoinfectionCOVID-19Streptococcal InfectionsStreptococcus pyogenesVirus DiseasesAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesSARS-CoV-2Switzerlandemm1Invasive group a Streptococcus (iGAS)M1UK clonePost-pandemic epidemiologyViral coinfection

Identifiers

PMID40762906
PMCPMC12619775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.